covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - szczepionki - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - szczepionki - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - szczepionki - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - szczepionki - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
montelukast aurovitas 5 mg tabletki do rozgryzania i żucia
aurovitas pharma polska sp. z o.o. - montelukastum - tabletki do rozgryzania i żucia - 5 mg
rywastigmina aurovitas 4,6 mg/24 h system transdermalny, plaster
aurovitas pharma polska sp. z o.o. - rivastigminum - system transdermalny, plaster - 4,6 mg/24 h
imatinib aurovitas 400 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - imatinibum - tabletki powlekane - 400 mg
escitalopram aurovitas 10 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - escitaloprami oxalas - tabletki powlekane - 10 mg
escitalopram aurovitas 15 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - escitaloprami oxalas - tabletki powlekane - 15 mg
escitalopram aurovitas 20 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - escitalopramum - tabletki powlekane - 20 mg